{"id":878039,"date":"2025-08-21T11:41:01","date_gmt":"2025-08-21T15:41:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"modified":"2025-08-21T11:41:01","modified_gmt":"2025-08-21T15:41:01","slug":"telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","title":{"rendered":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"},"content":{"rendered":"

<\/p>\n

Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–The DJS Law Group<\/a> announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX<\/a>) for violations of the securities laws.<\/p>\n

INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. On July 22, 2025, Telix disclosed it was the subject of a subpoena from the SEC “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Telix ADRs fell by more than 10.4% on July 23, 2025, based on this disclosure.<\/p>\n

\nIf you are a shareholder who suffered a loss, contact us to participate<\/a>.<\/p>\n

WHY DJS LAW GROUP?<\/b> DJS Law Group\u2019s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250821806044\/en\/<\/a><\/span><\/p>\n

\nDavid J. Schwartz
\n
DJS Law Group
\n
274 White Plains Road, Suite 1
\n
Eastchester, NY 10709
\n
Phone: 914-206-9742
\n
Email: David@djslawllp.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. On July 22, 2025, Telix disclosed it was the subject of a subpoena from the SEC “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Telix ADRs fell by more than 10.4% on July 23, 2025, … <\/p>\n

Continue reading “Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-878039","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTelix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. On July 22, 2025, Telix disclosed it was the subject of a subpoena from the SEC “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Telix ADRs fell by more than 10.4% on July 23, 2025, … Continue reading "Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T15:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\",\"datePublished\":\"2025-08-21T15:41:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\",\"name\":\"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-08-21T15:41:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","og_locale":"en_US","og_type":"article","og_title":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","og_description":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. On July 22, 2025, Telix disclosed it was the subject of a subpoena from the SEC “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Telix ADRs fell by more than 10.4% on July 23, 2025, … Continue reading \"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T15:41:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX","datePublished":"2025-08-21T15:41:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","name":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-08-21T15:41:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250821806044r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=878039"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=878039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=878039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=878039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}